2013
Quantitative Analysis of Estrogen Receptor Expression Shows SP1 Antibody Is More Sensitive Than 1D5
Welsh AW, Harigopal M, Wimberly H, Prasad M, Rimm DL. Quantitative Analysis of Estrogen Receptor Expression Shows SP1 Antibody Is More Sensitive Than 1D5. Applied Immunohistochemistry & Molecular Morphology 2013, 21: 139-147. PMID: 22820659, PMCID: PMC3482297, DOI: 10.1097/pai.0b013e31825d73b2.Peer-Reviewed Original Research
2012
Increasing Cytotechnologist Workload Above 100 Slides per Day Using the BD FocalPoint GS Imaging System Negatively Affects Screening Performance
Levi AW, Galullo P, Gordy K, Mikolaiski N, Schofield K, Elsheikh TM, Harigopal M, Chhieng DC. Increasing Cytotechnologist Workload Above 100 Slides per Day Using the BD FocalPoint GS Imaging System Negatively Affects Screening Performance. American Journal Of Clinical Pathology 2012, 138: 811-815. PMID: 23161714, DOI: 10.1309/ajcptydd9g2ncumf.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellCytodiagnosisDiagnostic ImagingFalse Negative ReactionsFemaleHumansImage Processing, Computer-AssistedMass ScreeningMedical Laboratory PersonnelQuality ControlSensitivity and SpecificityTime FactorsUterine Cervical DysplasiaUterine Cervical NeoplasmsVaginal SmearsWorkload
2011
Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells
Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL. Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells. Journal Of Clinical Oncology 2011, 29: 2978-2984. PMID: 21709197, PMCID: PMC3157961, DOI: 10.1200/jco.2010.32.9706.Peer-Reviewed Original ResearchConceptsER-positive patientsEstrogen receptorQuantitative immunofluorescenceBreast cancerTissue microarrayPositive cellsIndependent retrospective cohortsEstrogen receptor measurementsAssessment of survivalTMA cohortFalse-negative resultsRetrospective cohortER immunoreactivityTest discordancePrognostic outcomesIndependent cohortReceptor measurementsLimitations of immunohistochemistryPatientsDiscrepant casesCohortIHC methodPathologists' judgmentsDiscrepant resultsStandardized assays